KalVista Releases Data on Pediatric Hereditary Angioedema Treatment
KalVista Pharmaceuticals announced new data highlighting the burden of injectable on-demand treatment in children aged 2-11 with hereditary angioedema presented at ISPOR 2026 and the Eastern Allergy Conference. On-Demand Treatments for Hereditary Angioedema and Healthcare Resource Utilization in Pediatric Patients: A US Claims Database Analysis: Real-world claims data showed that while about two thirds of children aged 2-11 were prescribed IV pdC1INH-the only FDA-approved on-demand HAE treatment for this population-the majority of treatments utilized were off-label, suggesting families and providers may be seeking less invasive treatment options. Although the mean on-demand dosing rate was 0.43 per patient per month, the rate for pdC1INH was far less than that of icatibant. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Children: A caregiver survey found that nearly half of children did not receive on-demand treatment for their most recent HAE attack. Among children who did treat their last attack, 93.7% experienced anxiety about using injectable on-demand treatment, with 68.8% reporting extreme anxiety. Caregiver Burden Associated with Injectable On-Demand Treatment of Hereditary Angioedema Attacks in Children: The same caregiver survey found that during their child's last HAE attack, 43% occurred outside the home and 37% occurred while they were not with their child. 63% of caregivers had difficulty administering treatment and 31% took their child to a hospital or emergency center for treatment.
